Interestingly, treatment with an antiresorptive agent (zoledronic acid) and an anabolic drug (anti-SOST antibody) increased bone strength in preclinical myeloma models and may provide a rationale for relevant clinical studies [58,59]. The gene discussed is SOST; the disease is plasma cell myeloma.